Where we are with drugs for COVID-19?
Cardiovascular researcher Professor Martin Landray, from Oxford University, shares his thoughts
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
A single drug is unlikely to provide a ‘big win’ for treatment of COVID-19 — instead we are going to need to make the most of moderate benefits, according to a leading researcher and big data expert.
Speaking to delegates at the European Society of Cardiology’s virtual congress (ESC 2020) this week, Martin Landray, professor of medicine and epidemiology at Oxford University, UK, summarised progress in finding therapies for the disease so far.
It was worth remembering that there was unlikely to be a big win, he said, but that drugs providing moderate benefits would be important.
